
Shince Pharmaceuticals Private Limited
Trading chemical and pharmaceutical products, manufacturing drugs, medical equipment, and labware since 2008.
Trading chemical and pharmaceutical products, manufacturing drugs, medical equipment, and labware since 2008.
Shince Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 November 2008 and has a history of 16 years and four months. Its registered office is in Kanchipuram, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.97 Cr. The company has closed loans amounting to ₹1.25 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ramasamy Krishnamoorthy and Gowri Krishnamoorthy serve as directors at the Company.
Kanchipuram, Tamil Nadu, India
+91-XXXXXXXXXX
U24232TN2008PTC069950
069950
Private Limited Indian Non-Government Company
24 Nov 2008
30 Sep 2023
31 Mar 2023
Unlisted
Roc Chennai
Shince Pharmaceuticals Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Anti Inflammatory Drugs, Common Disease Medicines, Pharmaceutical Medicine, Cardiovascular Drugs & Medication, Diabetes Medicine, Arthritic Drugs, Antianginal Drugs, Pharmaceutical Tablets, Digestive System Drugs & Medicines.
Name | Designation | Appointment Date | Status |
---|---|---|---|
Ramasamy Krishnamoorthy ![]() | Director | 24-Nov-2008 | Current |
Gowri Krishnamoorthy ![]() | Director | 24-Nov-2008 | Current |
Shince Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 67.5% decrease. The company also saw a substantial fall in profitability, with a 63.42% decrease in profit. The company's net worth moved up by a moderate rise of 2.75%.
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
In 2023, Shince Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Ramasamy Krishnamoorthy and Gowri Krishnamoorthy are mutual person
Ramasamy Krishnamoorthy and Gowri Krishnamoorthy are mutual person
Ramasamy Krishnamoorthy and Gowri Krishnamoorthy are mutual person
₹19.70 M
₹12.50 M
Date | Lender | Amount | Status |
---|---|---|---|
22 Sep 2022 | Others | ₹1.01 Cr | Open |
04 Sep 2010 | State Bank Of India | ₹9.60 M | Open |
20 Nov 2009 | Karnataka Bank Limited | ₹1.25 Cr | Satisfied |
Unlock and access historical data on people associated with Shince Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Shince Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shince Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Shince Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2023 as per latest MCA records.
Shince Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Chennai.
A charge with Others amounted to Rs. 10.10 M with Charge ID 100615411 was registered on 22 Sep 2022.
A charge with State Bank Of India of Rs. 9.60 M registered on 04 Sep 2010 with Charge ID 10301214 was modified on 31 Dec 2021.
A charge registered on 20 Nov 2009 via Charge ID 10191110 with Karnataka Bank Limited was fully satisfied on 24 Sep 2010.
A charge with State Bank Of India amounted to Rs. 9.60 M with Charge ID 10301214 was registered on 04 Sep 2010.
Shince Pharmaceuticals Private Limited was incorporated on 24 Nov 2008.
The authorized share capital of Shince Pharmaceuticals Private Limited is ₹ 1.00 M and paid-up capital is ₹ 0.10 M.
Currently 2 directors are associated with Shince Pharmaceuticals Private Limited.
As per Ministry of Corporate Affairs (Mca), the registered address of Shince Pharmaceuticals Private Limited is 3/805A Mugalivakkam Main Road Madanandapuram, Porur India, Chennai, Tamil Nadu, 600116.
The corporate identification number (CIN) of Shince Pharmaceuticals Private Limited is U24232TN2008PTC069950 and the company number is 069950 as per Ministry of Corporate Affairs (MCA).
According to the financial reports for the fiscal year 2023, the revenue trend for Shince Pharmaceuticals Private Limited has fallen by -67.50%.
The financial reports for the fiscal year 2023 indicates that The net worth of Shince Pharmaceuticals Private Limited has experienced an upsurge of 2.75%.
As per the financial statements for fiscal Year 2023, The total open charges for Shince Pharmaceuticals Private Limited amount to ₹ 1.97 Cr.
The most recent Balance Sheet for Shince Pharmaceuticals Private Limited was filed with the ROC on 31 Mar 2023.